HIF activation causes synthetic lethality between the VHL tumor suppressor & the EZH1 histone methyltransferase

Abhishek A. Chakraborty, Eijiro Nakamura, Jun Qi, Amanda Creech, Jacob D. Jaffe, Joshiawa Paulk, Jesse S. Novak, Kshithija Nagulapalli, Samuel K. Mcbrayer, Glenn S. Cowley, Javier Pineda, Jiaxi Song, Yaoyu E. Wang, Steven A. Carr, David E. Root, Sabina Signoretti, James E. Bradner, William G. Kaelin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Inactivation of the von Hippel-Lindau tumor suppressor protein (pVHL) is the signature lesion in the most common form of kidney cancer, clear cell renal cell carcinoma (ccRCC). pVHL loss causes the transcriptional activation of hypoxia-inducible factor (HIF) target genes, including many genes that encode histone lysine demethylases. Moreover, chromatin regulators are frequently mutated in this disease. We found that ccRCC displays increased H3K27 acetylation and a shift toward mono- or unmethylated H3K27 caused by an HIF-dependent increase in H3K27 demethylase activity. Using a focused short hairpin RNA library, as well as CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR-Associated protein 9) and a pharmacological inhibitor, we discovered that pVHL-defective ccRCC cells are hyperdependent on the H3K27 methyltransferase EZH1 for survival. Therefore, targeting EZH1 could be therapeutically useful in ccRCC.

Original languageEnglish (US)
Article numbereaal5272
JournalScience Translational Medicine
Volume9
Issue number398
DOIs
StatePublished - Jul 12 2017
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Clustered Regularly Interspaced Short Palindromic Repeats
Von Hippel-Lindau Tumor Suppressor Protein
Neoplasms
Histone Demethylases
Kidney Neoplasms
Methyltransferases
Acetylation
Small Interfering RNA
Transcriptional Activation
Genes
Chromatin
Pharmacology
Synthetic Lethal Mutations
Hypoxia
histone methyltransferase
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chakraborty, A. A., Nakamura, E., Qi, J., Creech, A., Jaffe, J. D., Paulk, J., ... Kaelin, W. G. (2017). HIF activation causes synthetic lethality between the VHL tumor suppressor & the EZH1 histone methyltransferase. Science Translational Medicine, 9(398), [eaal5272]. https://doi.org/10.1126/scitranslmed.aal5272

HIF activation causes synthetic lethality between the VHL tumor suppressor & the EZH1 histone methyltransferase. / Chakraborty, Abhishek A.; Nakamura, Eijiro; Qi, Jun; Creech, Amanda; Jaffe, Jacob D.; Paulk, Joshiawa; Novak, Jesse S.; Nagulapalli, Kshithija; Mcbrayer, Samuel K.; Cowley, Glenn S.; Pineda, Javier; Song, Jiaxi; Wang, Yaoyu E.; Carr, Steven A.; Root, David E.; Signoretti, Sabina; Bradner, James E.; Kaelin, William G.

In: Science Translational Medicine, Vol. 9, No. 398, eaal5272, 12.07.2017.

Research output: Contribution to journalArticle

Chakraborty, AA, Nakamura, E, Qi, J, Creech, A, Jaffe, JD, Paulk, J, Novak, JS, Nagulapalli, K, Mcbrayer, SK, Cowley, GS, Pineda, J, Song, J, Wang, YE, Carr, SA, Root, DE, Signoretti, S, Bradner, JE & Kaelin, WG 2017, 'HIF activation causes synthetic lethality between the VHL tumor suppressor & the EZH1 histone methyltransferase', Science Translational Medicine, vol. 9, no. 398, eaal5272. https://doi.org/10.1126/scitranslmed.aal5272
Chakraborty, Abhishek A. ; Nakamura, Eijiro ; Qi, Jun ; Creech, Amanda ; Jaffe, Jacob D. ; Paulk, Joshiawa ; Novak, Jesse S. ; Nagulapalli, Kshithija ; Mcbrayer, Samuel K. ; Cowley, Glenn S. ; Pineda, Javier ; Song, Jiaxi ; Wang, Yaoyu E. ; Carr, Steven A. ; Root, David E. ; Signoretti, Sabina ; Bradner, James E. ; Kaelin, William G. / HIF activation causes synthetic lethality between the VHL tumor suppressor & the EZH1 histone methyltransferase. In: Science Translational Medicine. 2017 ; Vol. 9, No. 398.
@article{7bdddafb85a84fa5aa4935a5976a7782,
title = "HIF activation causes synthetic lethality between the VHL tumor suppressor & the EZH1 histone methyltransferase",
abstract = "Inactivation of the von Hippel-Lindau tumor suppressor protein (pVHL) is the signature lesion in the most common form of kidney cancer, clear cell renal cell carcinoma (ccRCC). pVHL loss causes the transcriptional activation of hypoxia-inducible factor (HIF) target genes, including many genes that encode histone lysine demethylases. Moreover, chromatin regulators are frequently mutated in this disease. We found that ccRCC displays increased H3K27 acetylation and a shift toward mono- or unmethylated H3K27 caused by an HIF-dependent increase in H3K27 demethylase activity. Using a focused short hairpin RNA library, as well as CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR-Associated protein 9) and a pharmacological inhibitor, we discovered that pVHL-defective ccRCC cells are hyperdependent on the H3K27 methyltransferase EZH1 for survival. Therefore, targeting EZH1 could be therapeutically useful in ccRCC.",
author = "Chakraborty, {Abhishek A.} and Eijiro Nakamura and Jun Qi and Amanda Creech and Jaffe, {Jacob D.} and Joshiawa Paulk and Novak, {Jesse S.} and Kshithija Nagulapalli and Mcbrayer, {Samuel K.} and Cowley, {Glenn S.} and Javier Pineda and Jiaxi Song and Wang, {Yaoyu E.} and Carr, {Steven A.} and Root, {David E.} and Sabina Signoretti and Bradner, {James E.} and Kaelin, {William G.}",
year = "2017",
month = "7",
day = "12",
doi = "10.1126/scitranslmed.aal5272",
language = "English (US)",
volume = "9",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "398",

}

TY - JOUR

T1 - HIF activation causes synthetic lethality between the VHL tumor suppressor & the EZH1 histone methyltransferase

AU - Chakraborty, Abhishek A.

AU - Nakamura, Eijiro

AU - Qi, Jun

AU - Creech, Amanda

AU - Jaffe, Jacob D.

AU - Paulk, Joshiawa

AU - Novak, Jesse S.

AU - Nagulapalli, Kshithija

AU - Mcbrayer, Samuel K.

AU - Cowley, Glenn S.

AU - Pineda, Javier

AU - Song, Jiaxi

AU - Wang, Yaoyu E.

AU - Carr, Steven A.

AU - Root, David E.

AU - Signoretti, Sabina

AU - Bradner, James E.

AU - Kaelin, William G.

PY - 2017/7/12

Y1 - 2017/7/12

N2 - Inactivation of the von Hippel-Lindau tumor suppressor protein (pVHL) is the signature lesion in the most common form of kidney cancer, clear cell renal cell carcinoma (ccRCC). pVHL loss causes the transcriptional activation of hypoxia-inducible factor (HIF) target genes, including many genes that encode histone lysine demethylases. Moreover, chromatin regulators are frequently mutated in this disease. We found that ccRCC displays increased H3K27 acetylation and a shift toward mono- or unmethylated H3K27 caused by an HIF-dependent increase in H3K27 demethylase activity. Using a focused short hairpin RNA library, as well as CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR-Associated protein 9) and a pharmacological inhibitor, we discovered that pVHL-defective ccRCC cells are hyperdependent on the H3K27 methyltransferase EZH1 for survival. Therefore, targeting EZH1 could be therapeutically useful in ccRCC.

AB - Inactivation of the von Hippel-Lindau tumor suppressor protein (pVHL) is the signature lesion in the most common form of kidney cancer, clear cell renal cell carcinoma (ccRCC). pVHL loss causes the transcriptional activation of hypoxia-inducible factor (HIF) target genes, including many genes that encode histone lysine demethylases. Moreover, chromatin regulators are frequently mutated in this disease. We found that ccRCC displays increased H3K27 acetylation and a shift toward mono- or unmethylated H3K27 caused by an HIF-dependent increase in H3K27 demethylase activity. Using a focused short hairpin RNA library, as well as CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR-Associated protein 9) and a pharmacological inhibitor, we discovered that pVHL-defective ccRCC cells are hyperdependent on the H3K27 methyltransferase EZH1 for survival. Therefore, targeting EZH1 could be therapeutically useful in ccRCC.

UR - http://www.scopus.com/inward/record.url?scp=85023781085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023781085&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aal5272

DO - 10.1126/scitranslmed.aal5272

M3 - Article

C2 - 28701475

AN - SCOPUS:85023781085

VL - 9

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 398

M1 - eaal5272

ER -